U
SPHS

UBS’s Sophiris Bio, Inc. SPHS Stock Holding History

UBS’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$6K Buy
+2,128
New +$5.99K ﹤0.01% 9405
2014
Q2 		– Sell
-312
Closed -$1K – 11439
2014
Q1 		$1K Buy
312
+256
+457% +$1K ﹤0.01% 10338
2013
Q4 		$0 Buy
+56
New +$237 ﹤0.01% 11442

Other funds holding SPHS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

UBS's SPHS Position: Q3 2014 in Review

UBS opened a new position in Sophiris Bio, Inc. (SPHS) in Q3 2014: 2,128 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #9405 among its holdings. This is a return to the name: UBS previously reported a position in SPHS as recently as Q1 2014.

UBS first reported a position in SPHS in Q4 2013 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold SPHS as of Q3 2014.

  • UBS held 2,128 shares of Sophiris Bio, Inc. worth $6K as of Q3 2014.
  • Sophiris Bio, Inc. was a new UBS position in Q3 2014.
  • Sophiris Bio, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9405 holding.
  • UBS first reported a position in Sophiris Bio, Inc. in Q4 2013 and has held it in 3 quarters since.
  • 21 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.